|
|
Scientists at Van Andel Research Institute (VARI) have identified a gene that would be ideal for gene therapy in the people suffering from bone marrow disease, Myelodysplastic Syndrome (MDS).
In the process of their research, the scientists found a new gene called RhoB which could be a potential therapeutic source.
"Using our genetic models, we've been able to provide a better understanding of underlying molecular defects that drive the malignant progression of MDS," said Dr. Art Alberts, Principal Scientific Investigator (VARI).
"The genes that we've focused on in this study might have a role not only in Leukemia, but in solid tumours as well," Alberts added.
Previously, the researchers had identified a gene called Drf1, which was an important precursor for the development of MDS. Now the new RhoB gene is also important in the onset of that disease.
They concluded that, lack of the protein useful for the gene would accelerate the disease and it’s better to check the RhoB levels in the MSD patients who are in advanced stages.
"Our goal is to identify novel therapeutic targets and develop new drugs that affect their activity, but also to find ways to improve upon existing therapeutic strategies that are often associated with deleterious side effects," Alberts reiterated.
These findings have been published in the current issue of PLoS ONE.
